抑瘤素M调控骨稳态的研究进展

doi:10.13701/j.cnki.kqyxyj.2019.11.005

口腔医学研究 ›› 2019, Vol. 35 ›› Issue (11): 1026-1029.DOI: 10.13701/j.cnki.kqyxyj.2019.11.005

抑瘤素M调控骨稳态的研究进展

冯丽华^1,2, 夏海斌^1*

1. 武汉大学口腔医学院种植科湖北武汉 430079;
2. 口腔基础医学省部共建国家重点实验室培育基地和口腔生物医学教育部重点实验室湖北武汉 430079

收稿日期:2018-12-12 出版日期:2019-11-28 发布日期:2019-11-21
通讯作者: 夏海斌,E-mail:xhaibin@whu.edu.cn
作者简介:冯丽华(1992~ ),女,湖北恩施人,硕士在读,主要从事口腔基础及临床的研究工作。
基金资助:
国家自然科学基金(编号:31570982)

Research Progress on the Regulation of Bone Homeostasis by Oncostatin M

FENG Lihua^1,2, XIA Haibin^1*

1. Department of Implantology, School of Stomatology, Wuhan University, Wuhan 430079, China;
2. The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, Wuhan University, Wuhan 430079, China

Received:2018-12-12 Online:2019-11-28 Published:2019-11-21

摘要/Abstract

摘要： 骨组织终生处于骨吸收和骨生成的动态平衡状态,即骨稳态。机体内多种细胞和细胞因子可通过复杂的信号网络对骨稳态进行调控。抑瘤素M(oncostatin M,OSM)作为白细胞介素-6(interleukin-6,IL-6) 家族成员,是一种具有多种生物学活性的细胞因子。近期研究结果表明,成骨细胞、骨细胞和巨噬细胞等能通过分泌OSM调节骨形成和骨吸收,OSM在骨稳态的维持中发挥重要的双向调节作用。本文拟对OSM调控骨稳态的研究进展作一综述。

关键词: 抑瘤素, 骨稳态, 成骨细胞, 破骨细胞

Abstract: Bone tissue is in the dynamic equilibrium state of bone resorption and bone formation throughout life, namely bone homeostasis. In the body, a complex network of cells and cytokines regulates bone homeostasis. Oncostatin M (OSM), as a member of the IL-6 family, is a cytokine with multiple biological activities. Recent studies have shown that osteoblasts, osteocytes, and macrophages can regulate bone formation and bone resorption by secreting OSM, which plays an important role in bidirectional regulation of bone homeostasis. This paper reviews the research progress of OSM on bone homeostasis.

Key words: oncostatin M, bone homeostasis, osteoblast, osteoclast

冯丽华, 夏海斌. 抑瘤素M调控骨稳态的研究进展[J]. 口腔医学研究, 2019, 35(11): 1026-1029.

FENG Lihua, XIA Haibin. Research Progress on the Regulation of Bone Homeostasis by Oncostatin M[J]. Journal of Oral Science Research, 2019, 35(11): 1026-1029.

参考文献

[1] Ginaldi L, De Martinis M. Osteoimmunology and beyond [J]. Curr Med Chem, 2016, 23(33): 3754-3774.
[2] Tonna S, Sims NA. Talking among ourselves: paracrine control of bone formation within the osteoblast lineage [J]. Calcif Tissue Int, 2014, 94(1): 35-45.
[3] Sims NA. Cell-specific paracrine actions of IL-6 family cytokines from bone, marrow and muscle that control bone formation and resorption [J]. Int J Biochem Cell Biol, 2016, 79:14-23.
[4] Ryan RE, Martin B, Mellor L, et al. Oncostatin M binds to extracellular matrix in a bioactive conformation: Implications for inflammation and metastasis [J]. Cytokine, 2015, 72(1): 71-85.
[5] Sims NA, Quinn JM. Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease [J]. Bonekey Rep, 2014, 3: 527.
[6] Richards CD. The enigmatic cytokine oncostatin M and roles in disease [J]. ISRN Inflamm, 2013, 2013: 512103.
[7] Zarling JM, Shoyab M, Marquardt H, et al. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells [J]. Proc Natl Acad Sci U S A, 1986, 83(24):9739-9743.
[8] Hermanns HM. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology [J]. Cytokine Growth Factor Rev, 2015, 26(5): 545-558.
[9] de Hooge AS, van de Loo FA, Bennink MB, et al. Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-κB ligand [J]. Am J Pathol, 2002, 160(5):1733-1743.
[10] Moxham JP. Oncostatin-M enhances osteoinduction in a rabbit critical calvarial defect model [J]. Laryngoscope, 2007, 117(10):1790-1797.
[11] Walker EC, Johnson RW, Hu Y, et al. Murine oncostatin M acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an effect that protects bone mass [J]. J Biol Chem, 2016, 291(41): 21703-21716.
[12] Guihard P, Boutet M, Brounais-Le Royer B, et al. Oncostatin M, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury [J]. Am J Pathol, 2015, 185(3): 765-775.
[13] Sato F, Miyaoka Y, Miyajima A, et al. Oncostatin M maintains the hematopoietic microenvironment in the bone marrow by modulating adipogenesis and osteogenesis [J]. PLoS One, 2014, 9(12): e116209.
[14] Sims NA, Walsh NC. GP130 cytokines and bone remodelling in health and disease [J]. BMB Rep, 2010, 43(8):513-523.
[15] Johnson RW, Brennan HJ, Vrahnas C, et al. The primary function of gp130 signaling in osteoblasts is to maintain bone formation and strength, rather than promote osteoclast formation [J]. J Bone Miner Res, 2014, 29(6):1492-1505.
[16] Standal T, Johnson RW, Mcgregor NE, et al. gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation [J]. J Endocrinol, 2014, 223(2): 181-190.
[17] Dey G, Radhakrishnan A, Syed N, et al. Signaling network of Oncostatin M pathway [J]. J Cell Commun Signal, 2013, 7(2):103-108.
[18] Miyaoka Y, Tanaka M, Naiki T, et al. Oncostatin M inhibits adipogenesis through the RAS/ERK and STAT5 signaling pathways [J]. J Biol Chem, 2006, 281(49): 37913-37920.
[19] Song HY, Jeon ES, Kim JI, et al. Oncostatin M promotes osteogenesis and suppresses adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells [J]. J Cell Biochem, 2007, 101(5): 1238-1251.
[20] Smyth DC, Takenaka S, Yeung C, et al. Oncostatin M regulates osteogenic differentiation of murine adipose-derived mesenchymal progenitor cells through a PKCdelta-dependent mechanism [J]. Cell Tissue Res, 2015, 360(2): 309-319.
[21] Zou F, Xu JC, Wu GH, et al. Effects of oncostatin M on cell proliferation and osteogenic differentiation in C3H10T1/2 [J]. J Musculoskelet Neuronal Interact, 2016, 16(4):377-385.
[22] Zhang Y, Böse T, Unger RE, et al. Macrophage type modulates osteogenic differentiation of adipose tissue MSCs [J]. Cell Tissue Res, 2017, 369(2):273-286.
[23] Guihard P, Danger Y, Brounais B, et al. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling [J]. Stem Cells, 2012, 30(4):762-772.
[24] Nicolaidou V, Wong MM, Redpath AN, et al. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation [J]. PLoS One, 2012, 7(7): e39871.
[25] Fernandes TJ, Hodge JM, Singh PP, et al. Cord blood-derived macrophage-lineage cells rapidly stimulate osteoblastic maturation in mesenchymal stem cells in a glycoprotein-130 dependent manner [J]. PLoS One, 2013, 8(9): e73266.
[26] Hirata E, Miyako E, Hanagata N, et al. Carbon nanohorns allow acceleration of osteoblast differentiation via macrophage activation [J]. Nanoscale, 2016, 8(30): 14514-14522.
[27] Ni J, Yuan XM, Yao Q, et al. OSM is overexpressed in knee osteoarthritis and Notch signaling is involved in the effects of OSM on MC3T3-E1 cell proliferation and differentiation [J]. Int J Mol Med, 2015, 35(6): 1755-1760.
[28] Zheng W, Guan J. Oncostatin M promotes the osteogenic differentiation of mouse MC3T3-E1 osteoblasts through the regulation of monocyte chemotactic protein-1 [J]. Mol Med Rep, 2018, 18(3): 2523-2530.
[29] Jay PR, Centrella M, Lorenzo J, et al. Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption [J]. Endocrinology, 1996, 137(4): 1151-1158.
[30] Hui W, Cawston TE, Richards CD, et al. A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL [J]. Arthritis Res Ther, 2005, 7(1): R57-R64.
[31] Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis [J]. Endocrinology, 2005, 146(11): 4577-4583.
[32] Walker EC, Poulton IJ, Mcgregor NE, et al. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo [J]. J Bone Miner Res,2012,27(4):902-912.
[33] Walker EC, Johnson RW, Hu Y, et al. Murine oncostatin M acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an effect that protects bone mass [J]. J Biol Chem, 2016, 291(41): 21703-21716.

抑瘤素M调控骨稳态的研究进展

Research Progress on the Regulation of Bone Homeostasis by Oncostatin M

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	苏娟娟, 朱永翠, 张文玲. 连翘苷对牙周炎大鼠p38 MAPK/c-Fos信号通路及破骨细胞活化的影响[J]. 口腔医学研究, 2021, 37(1): 33-38.
[2]	陈振宇, 潘颖菁, 张艳, 贺玺, 黄达鸿. 葛根素对高浓度糖皮质激素环境下MC3T3-E1前成骨细胞生物学性能的影响[J]. 口腔医学研究, 2020, 36(6): 544-547.
[3]	何梦婷, 白丁. 牙囊在牙萌出的作用及其调控机制研究进展[J]. 口腔医学研究, 2020, 36(2): 107-110.
[4]	唐晓悦, 朱浩, 曹灿. 白藜芦醇通过沉默信息调节因子/叉头转录因子通路对高糖诱导成骨细胞增殖、分化的影响[J]. 口腔医学研究, 2020, 36(1): 79-84.
[5]	张晓燕, 刘运新, 吴铁. 丹参素对牙槽骨成骨细胞细胞核因子-κB受体活化因子配体/骨保护素表达的影响研究[J]. 口腔医学研究, 2019, 35(9): 894-897.
[6]	胡英英, 哈珊珊, 朱宁静, 宋亚玲, 汪昌宁. 雌激素作用下罗格列酮对RAW264.7向破骨细胞分化的影响[J]. 口腔医学研究, 2019, 35(5): 502-506.
[7]	阮国宪, 高丽卿, 邓立. 周期性压应力诱导髁突软骨细胞分泌促破骨因子的研究[J]. 口腔医学研究, 2019, 35(4): 372-376.
[8]	陈燕, 姜胜军, 彭友俭. 骨髓间充质干细胞来源的外泌体对成骨细胞增殖和分化的影响[J]. 口腔医学研究, 2019, 35(4): 401-404.
[9]	史东梅, 徐慧君, 左美娜, 仉红, 张咪, 吴赛璇, 董明, 牛卫东. 粪肠球菌脂磷壁酸作用的炎症微环境下磷脂酶 Cγ表达研究[J]. 口腔医学研究, 2019, 35(11): 1084-1088.
[10]	王佳, 张文静, 韩祥祯, 周琦琪, 何惠宇. 巨噬细胞集落刺激因子过表达对信号通路中破骨相关因子的影响[J]. 口腔医学研究, 2019, 35(11): 1089-1093.
[11]	陈雅文,王海丞,董伟杰. A结构域阳性纤维连接蛋白促进破骨细胞形成及根尖囊肿骨质破坏[J]. 口腔医学研究, 2018, 34(9): 952-955.
[12]	陆蓓. 重组人骨形态发生蛋白-9对人牙周膜成纤维细胞成骨分化的影响[J]. 口腔医学研究, 2018, 34(8): 857-861.
[13]	龙甜, 程志刚. 含锶/锌钙磷涂层对RAW264.7破骨细胞体外影响的研究[J]. 口腔医学研究, 2018, 34(8): 910-912.
[14]	葛林虎, 方颖, 查骏, 李军, 万绵佳, 王丽萍. 浓缩生长因子促进大鼠种植体骨结合的实验研究[J]. 口腔医学研究, 2018, 34(7): 721-725.
[15]	全雨坚, 李德超, 李慕勤, 张慧明, 刘洋. 纯钛表面载环肽c(RGDfk)对类成骨细胞增殖和信号转导通路的影响[J]. 口腔医学研究, 2018, 34(6): 609-613.